Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOGEN INC.BIIB · Entity 1675 | EVP Pres Int'l & Global Hd GTO | July 03, 2017 | July 05, 2017 |
| Sarepta Therapeutics, Inc.SRPT · Entity 4426 | Director | March 10, 2017 | March 15, 2017 |
| Vor Biopharma Inc.VOR · Entity 4763 | Director · CEO and Chairman | December 05, 2025 | December 09, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOGEN INC.
Report date July 03, 2017 · Filed July 05, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2020-07-03 | Direct | 4,660 |
Reported balance
After 2017-07-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-07-03 · Grant · Acquired 4,660 · Balance 4,660 F1: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). |
Filing footnotes · ownership attribution and instrument terms
F1: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]).
Sarepta Therapeutics, Inc.
Report date March 10, 2017 · Filed March 15, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,000 |
Reported balance
After 2017-03-10 transaction · row 1
1 source rowRow 1 · 2017-03-10 · Grant · Acquired 1,000 · Balance 2,000 F1: Each restricted stock unit represents the right to receive one share of common stock and will vest in full on the first year anniversary of Sarepta's 2017 Annual Meeting of Stockholders. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $32.63 · Expires 2027-03-10 | Direct | 12,350 |
Reported balance
After 2017-03-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-03-10 · Grant · Acquired 12,350 · Balance 12,350 F2: The option will vest at a rate of 1/24th of the total option amount granted on a monthly basis over two years commencing on the first monthly anniversary of Sarepta's 2017 Annual Meeting of Stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents the right to receive one share of common stock and will vest in full on the first year anniversary of Sarepta's 2017 Annual Meeting of Stockholders.
F2: The option will vest at a rate of 1/24th of the total option amount granted on a monthly basis over two years commencing on the first monthly anniversary of Sarepta's 2017 Annual Meeting of Stockholders.
Vor Biopharma Inc.
Report date December 05, 2025 · Filed December 09, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.80 · Expires 2035-06-25 | Direct | 0 |
Reported balance
After 2025-12-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-12-05 · Disposition to issuer · Disposed 4,164,831 · Balance 0 F1: On September 18, 2025, the Issuer effected a 1-for-20 reverse stock split. The amounts herein reflect the reverse stock split. F2: On December 5, 2025, pursuant to the terms of the Issuer's Amended and Restated 2021 Equity Incentive Plan (the "2021 Plan") and 2023 Inducement Plan (the "Inducement Plan"), the Issuer's Board of Directors approved a stock option award repricing, effective as of December 5, 2025 (the "Effective Date"). Except for the new exercise price (see footnote 4 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3: 1/4th of the shares underlying the option vest on June 26, 2026, with the remainder vesting in equal monthly installments over 3 years, in each case subject to the Reporting Person's continued service as of each such date. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.18 · Expires 2035-06-25 | Direct | 4,164,831 |
Reported balance
After 2025-12-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-12-05 · Grant · Acquired 4,164,831 · Balance 4,164,831 F4: The exercise price of the stock option award is $8.18 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date. Under the terms of the stock option award repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period" commenced on the Effective Date and ends upon the earliest of (i) the date 24 months following the Effective Date; (ii) a Change in Control during the optionholder's Continuous Service (each as defined in the Inducement Plan); and (iii) 30 days prior to the option's original expiration date. F2: On December 5, 2025, pursuant to the terms of the Issuer's Amended and Restated 2021 Equity Incentive Plan (the "2021 Plan") and 2023 Inducement Plan (the "Inducement Plan"), the Issuer's Board of Directors approved a stock option award repricing, effective as of December 5, 2025 (the "Effective Date"). Except for the new exercise price (see footnote 4 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3: 1/4th of the shares underlying the option vest on June 26, 2026, with the remainder vesting in equal monthly installments over 3 years, in each case subject to the Reporting Person's continued service as of each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: On September 18, 2025, the Issuer effected a 1-for-20 reverse stock split. The amounts herein reflect the reverse stock split.
F2: On December 5, 2025, pursuant to the terms of the Issuer's Amended and Restated 2021 Equity Incentive Plan (the "2021 Plan") and 2023 Inducement Plan (the "Inducement Plan"), the Issuer's Board of Directors approved a stock option award repricing, effective as of December 5, 2025 (the "Effective Date"). Except for the new exercise price (see footnote 4 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
F3: 1/4th of the shares underlying the option vest on June 26, 2026, with the remainder vesting in equal monthly installments over 3 years, in each case subject to the Reporting Person's continued service as of each such date.
F4: The exercise price of the stock option award is $8.18 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date. Under the terms of the stock option award repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period" commenced on the Effective Date and ends upon the earliest of (i) the date 24 months following the Effective Date; (ii) a Change in Control during the optionholder's Continuous Service (each as defined in the Inducement Plan); and (iii) 30 days prior to the option's original expiration date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 05, 2025 Filed Dec 9, 2025 13:00 UTC | Vor Biopharma Inc. VOR · Entity 4763 | GrantEmployee Stock Option (right to buy) · Derivative | 4,164,831 | $0.00 Strike: $8.18 | $0.00 |
DisclosureSEC source: 0001654979-25-000006 · form4-12092025_081201.xml · derivative · entry 2 Kress Jean-Paul · CIK 0001654979 · Director · CEO and Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,164,831 Underlying: Common Stock · 4,164,831 shares Expires 2035-06-25 F4 · derivative.exercise_price: The exercise price of the stock option award is $8.18 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date. Under the terms of the stock option award repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period" commenced on the Effective Date and ends upon the earliest of (i) the date 24 months following the Effective Date; (ii) a Change in Control during the optionholder's Continuous Service (each as defined in the Inducement Plan); and (iii) 30 days prior to the option's original expiration date. F2 · kind: On December 5, 2025, pursuant to the terms of the Issuer's Amended and Restated 2021 Equity Incentive Plan (the "2021 Plan") and 2023 Inducement Plan (the "Inducement Plan"), the Issuer's Board of Directors approved a stock option award repricing, effective as of December 5, 2025 (the "Effective Date"). Except for the new exercise price (see footnote 4 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: 1/4th of the shares underlying the option vest on June 26, 2026, with the remainder vesting in equal monthly installments over 3 years, in each case subject to the Reporting Person's continued service as of each such date. Read SEC document |
| December 05, 2025 Filed Dec 9, 2025 13:00 UTC | Vor Biopharma Inc. VOR · Entity 4763 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 4,164,831 | $0.00 Strike: $17.80 | $0.00 |
DisclosureSEC source: 0001654979-25-000006 · form4-12092025_081201.xml · derivative · entry 1 Kress Jean-Paul · CIK 0001654979 · Director · CEO and Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,164,831 shares Expires 2035-06-25 F1 · derivative.exercise_price: On September 18, 2025, the Issuer effected a 1-for-20 reverse stock split. The amounts herein reflect the reverse stock split. F2 · kind: On December 5, 2025, pursuant to the terms of the Issuer's Amended and Restated 2021 Equity Incentive Plan (the "2021 Plan") and 2023 Inducement Plan (the "Inducement Plan"), the Issuer's Board of Directors approved a stock option award repricing, effective as of December 5, 2025 (the "Effective Date"). Except for the new exercise price (see footnote 4 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · shares: On September 18, 2025, the Issuer effected a 1-for-20 reverse stock split. The amounts herein reflect the reverse stock split. F3 · derivative.exercise_date: 1/4th of the shares underlying the option vest on June 26, 2026, with the remainder vesting in equal monthly installments over 3 years, in each case subject to the Reporting Person's continued service as of each such date. F1 · derivative.underlying_shares: On September 18, 2025, the Issuer effected a 1-for-20 reverse stock split. The amounts herein reflect the reverse stock split. Read SEC document |
| June 26, 2025 Filed Jun 27, 2025 20:10 UTC | Vor Biopharma Inc. VOR · Entity 4763 | GrantEmployee Stock Option (right to buy) · Derivative | 83,296,638 | $0.00 Strike: $0.89 | $0.00 |
DisclosureSEC source: 0001415889-25-018365 · form4-06272025_080605.xml · derivative · entry 1 Kress Jean-Paul · CIK 0001654979 · Director · CEO and Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,296,638 Underlying: Common Stock · 83,296,638 shares Expires 2035-06-25 F1 · derivative.exercise_date: 1/4th of the shares underlying the option vest on June 26, 2026, with the remainder vesting in equal monthly installments over 3 years, in each case subject to the Reporting Person's continued service as of each such date. Read SEC document |
| July 03, 2017 Filed Jul 5, 2017 23:18 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 4,660 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-023131 · form4.xml · derivative · entry 1 Kress Jean-Paul · CIK 0001654979 · EVP Pres Int'l & Global Hd GTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,660 Underlying: Common Stock · 4,660 shares Expires 2020-07-03 F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| March 10, 2017 Filed Mar 15, 2017 01:42 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 12,350 | $0.00 Strike: $32.63 | $0.00 |
DisclosureSEC source: 0001209191-17-020684 · doc4.xml · derivative · entry 2 Kress Jean-Paul · CIK 0001654979 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,350 Underlying: Common Stock · 12,350 shares Expires 2027-03-10 F2 · derivative.exercise_date: The option will vest at a rate of 1/24th of the total option amount granted on a monthly basis over two years commencing on the first monthly anniversary of Sarepta's 2017 Annual Meeting of Stockholders. Read SEC document |
| March 10, 2017 Filed Mar 15, 2017 01:42 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-020684 · doc4.xml · nonDerivative · entry 1 Kress Jean-Paul · CIK 0001654979 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 F1 · shares: Each restricted stock unit represents the right to receive one share of common stock and will vest in full on the first year anniversary of Sarepta's 2017 Annual Meeting of Stockholders. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.